Proprietary Business Strategy > Proprietary History and Strategy

In 1997, Barr announced plans to extend its pharmaceutical research and development activities into proprietary product development.

In January 2000, the Company dramatically strengthened its commitment to proprietary product development with the formation of Duramed Research. The Duramed Research team has extensive brand product experience in the areas of clinical trials, toxicology, regulatory, pharmacokinetics, statistics, medical writing and product commercialization. The primary focus of Duramed Research is the expansion of a robust strategic proprietary product portfolio through the submission of New Drug Applications (NDAs).

The Company’s strategy is designed to exploit the weaknesses of mega-companies that their size creates. It is no longer possible for a global brand company to effectively pursue products that would be considered of nominal-to-limited potential. However, this creates a reservoir of product opportunities for a company such as Duramed, where the prospect of developing a product in the $10 - 150 million annual sales range creates significant growth potential.